000885839 001__ 885839
000885839 005__ 20230217124531.0
000885839 0247_ $$2doi$$a10.1111/ene.14435
000885839 0247_ $$2ISSN$$a1351-5101
000885839 0247_ $$2ISSN$$a1468-1331
000885839 0247_ $$2ISSN$$a1471-0552
000885839 0247_ $$2Handle$$a2128/25970
000885839 0247_ $$2pmid$$apmid:32644211
000885839 0247_ $$2WOS$$aWOS:000578714700048
000885839 037__ $$aFZJ-2020-04125
000885839 041__ $$aEnglish
000885839 082__ $$a610
000885839 1001_ $$0P:(DE-HGF)0$$aGoereci, Y.$$b0
000885839 245__ $$aClearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin‐2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome
000885839 260__ $$aOxford$$bBlackwell Science91133$$c2020
000885839 264_1 $$2Crossref$$3online$$bWiley$$c2020-10-13
000885839 264_1 $$2Crossref$$3print$$bWiley$$c2020-11-01
000885839 264_1 $$2Crossref$$3print$$bWiley$$c2020-11-01
000885839 3367_ $$2DRIVER$$aarticle
000885839 3367_ $$2DataCite$$aOutput Types/Journal article
000885839 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1603787252_19249
000885839 3367_ $$2BibTeX$$aARTICLE
000885839 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000885839 3367_ $$00$$2EndNote$$aJournal Article
000885839 520__ $$aA 71‐year‐old Caucasian man presented with dysarthria and fluctuating hypoesthesia of the right upper limb in early 2019. Brain magnetic resonance imaging (MRI) demonstrated T2/fluid attenuated inversion recovery hyperintense lesions in the left parietal cortical grey matter and adjacent white matter compatible with embolic stroke of undetermined source. Eight weeks later, symptoms had further progressed with loss of adequate communication, disturbance of fine motor skills, ataxia and neuropsychiatric symptoms. Widespread disease on brain MRI and the detection of JC polyomavirus (JCPyV) DNA from cerebrospinal fluid (CSF) confirmed the diagnosis of progressive multifocal leukoencephalopathy (PML) [1]. Bone marrow biopsy revealed normal findings, and no underlying cause of reduced immunocompetence was identified. Despite rehabilitation, treatment with mirtazapine and two cycles of interleukin‐2 (IL‐2) (1 mio IE/m² sc once per day for 7 days) administered 2 weeks apart [1, 2], symptoms and MRI lesions further progressed, with complete immobility and severe dysphagia. Nine weeks after definite PML diagnosis and 4 weeks after the last IL‐2 dose, a total of three cycles of monthly infusions of pembrolizumab were applied. At the initiation of the third cycle of pembrolizumab, cognitive performance and fine motor skills had temporarily improved, and the patient had regained the ability to walk a few steps with assistance. On MRI, no increase in lesion load and no signs of an immune reconstitution inflammatory syndrome were noted. JCPyV DNA, after a decline that started already following the IL‐2 therapy, was no longer detected in CSF, collectively suggesting PML remission (Fig. 1). Enzyme‐linked immunosorbent assays revealed increasing JCPyV‐specific antibody titers in blood and CSF (AIJCPyV > 1.5 [3]). A pembrolizumab effect was indicated by reduced programmed cell death protein 1 (PD‐1) expression on peripheral CD4+ and CD8+ T cells after the treatment. Also, during the disease course of PML and following pembrolizumab treatment, proportions of innate immune cells (CD56dimCD16‐cytotoxic NK cells, CD14+ CD16 classical and CD14dim CD16+ non‐classical monocytes and CD11+ dendritic cells) and pro‐inflammatory cytokines and chemokine increased (Appendix S1, Table S1). Four weeks following the last infusion with pembrolizumab, aspiration pneumonia was suspected, and the patient received intravenous piperacillin/tazobactam 4/0.5 g three times per day for 7 days with temporary relief of symptoms. No causative bacteria were detected from blood cultures. Six weeks post‐pembrolizumab treatment, respiratory distress occurred again, and the general clinical condition further deteriorated. The patient and his legal custodians decided not to receive further hospital care, upon considering the severe and persistent disability, and the patient died shortly thereafter. As an autopsy was not performed, alternative causes of respiratory distress, such as autoimmune pneumonitis that might occur as an adverse event of pembrolizumab therapy, could not be ruled out. 
000885839 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000885839 542__ $$2Crossref$$i2020-10-13$$uhttp://creativecommons.org/licenses/by-nc/4.0/
000885839 542__ $$2Crossref$$i2020-10-13$$uhttp://doi.wiley.com/10.1002/tdm_license_1.1
000885839 588__ $$aDataset connected to CrossRef
000885839 7001_ $$0P:(DE-HGF)0$$aSchweitzer, F.$$b1
000885839 7001_ $$0P:(DE-HGF)0$$aWellstein, A.$$b2
000885839 7001_ $$0P:(DE-HGF)0$$aSilling, S.$$b3
000885839 7001_ $$0P:(DE-HGF)0$$aBorchmann, S.$$b4
000885839 7001_ $$0P:(DE-HGF)0$$aTresckow, B.$$b5
000885839 7001_ $$0P:(DE-HGF)0$$aAdams, O.$$b6
000885839 7001_ $$0P:(DE-HGF)0$$aMartin, R.$$b7
000885839 7001_ $$0P:(DE-HGF)0$$aSchlamann, M.$$b8
000885839 7001_ $$0P:(DE-HGF)0$$aSchroeter, M.$$b9
000885839 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b10
000885839 7001_ $$0P:(DE-HGF)0$$aWattjes, M. P.$$b11
000885839 7001_ $$00000-0002-3510-9255$$aWarnke, C.$$b12$$eCorresponding author
000885839 77318 $$2Crossref$$3journal-article$$a10.1111/ene.14435$$bWiley$$d2020-10-13$$n11$$p2375-2377$$tEuropean Journal of Neurology$$v27$$x1351-5101$$y2020
000885839 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.14435$$gVol. 27, no. 11, p. 2375 - 2377$$n11$$p2375-2377$$tEuropean journal of neurology$$v27$$x1351-5101$$y2020
000885839 8564_ $$uhttps://juser.fz-juelich.de/record/885839/files/Goereci_EurJNeurol_2020_Clearance%20of%20JC%20polyomavirus%20from%20cerebrospinal%20fluid%20following%20treatment%20with%20interleukin%202%20and%20pembrolizumab.pdf$$yOpenAccess
000885839 8564_ $$uhttps://juser.fz-juelich.de/record/885839/files/Goereci_EurJNeurol_2020_Clearance%20of%20JC%20polyomavirus%20from%20cerebrospinal%20fluid%20following%20treatment%20with%20interleukin%202%20and%20pembrolizumab.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000885839 909CO $$ooai:juser.fz-juelich.de:885839$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000885839 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b10$$kFZJ
000885839 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000885839 9141_ $$y2020
000885839 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000885839 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000885839 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000885839 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2015
000885839 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000885839 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000885839 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000885839 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000885839 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000885839 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000885839 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000885839 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000885839 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000885839 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000885839 920__ $$lyes
000885839 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000885839 980__ $$ajournal
000885839 980__ $$aVDB
000885839 980__ $$aUNRESTRICTED
000885839 980__ $$aI:(DE-Juel1)INM-3-20090406
000885839 9801_ $$aFullTexts
000885839 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0b013e31828c2fa1
000885839 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1177/1756285615621029
000885839 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/ana.24153
000885839 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1815039
000885839 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMc1817193
000885839 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMc1816198
000885839 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/NXI.0000000000000629